Sector not mapped · coverage Nov 27, 2024–Nov 21, 2025
Estimated market comparison · not an official filing fact
Available with Pro
Average post-trade price move across enriched rows. It is historical, sample-limited, does not account for exact execution prices or portfolio weights, and is not evidence that the filing activity caused a market move.
Disclosure alert preview
Based on a real public filing
Lisa C. McClain
$1K - $15K
This watch matched after the disclosure became public. It is not a real-time trade signal. Source checked Aug 13, 2026.
Official filingThis page summarizes public STOCK Act disclosures involving GSK. It is useful for seeing which lawmakers reported GSK transactions, how many filings are visible, the buy/sell mix, and whether the newest public filing describes a recent or delayed trade.
Nov 21, 2025
Public House and Senate STOCK Act disclosures normalized by Congressional Trader.
Filing date can trail transaction date. This page is for research and monitoring, not investment advice.
Congressional Trader tracks 12 public STOCK Act disclosures for GSKacross 5 lawmakers. This page separates purchases from sales, shows filing delays, and links each disclosure back to the individual politician profile when available.
The most recent GSK filing shown here was filed on Nov 21, 2025 by Lisa C. McClain as a sale. Related lawmakers include Lisa C. McClain, Bruce Westerman, Val T. Hoyle, Marjorie Taylor Greene, Robert B. Aderholt.
Unlock 30/90-day post-trade summaries, committee overlap, and CSV-oriented research views for high-intent ticker research.
Compare Pro plansRecent GSK disclosures include Lisa C. McClain, Bruce Westerman, Val T. Hoyle, Marjorie Taylor Greene, Robert B. Aderholt.
The visible sample currently shows 6 purchases and 6 sales or partial sales.
No. This page summarizes public filings for research and monitoring. It is not investment advice.
